ONC
BeiGene, Ltd.
347.50$
-2.4%
vs. previous close
Closing price · As of: Aug 14, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +117.8% | +247.5% | +157.9% | +115.0% | -28.3% | +247.4% | +52.4% | -25.3% | -9.0% | +2.0% | +38.3% | |
| – | +125.2% | +252.3% | +144.0% | +112.8% | -39.7% | +323.0% | +53.5% | -31.6% | -19.3% | -5.0% | +56.2% | |
| – | +28.6% | +389.8% | +173.8% | +197.6% | -13.3% | +123.6% | +216.6% | -11.6% | -18.0% | -17.2% | +73.1% | |
| – | +126.3% | +266.4% | +127.5% | +112.7% | -44.8% | +373.2% | +42.3% | -31.5% | -30.1% | -17.2% | +73.1% | |
| – | – | – | – | +68.8% | +42.7% | -14.8% | +728.1% | -60.2% | +99.0% | +79.1% | +25.1% | |
| – | – | – | – | +48.6% | +75.8% | +212.7% | +171.7% | +16.4% | +47.4% | +19.0% | +22.9% | |
| – | – | – | – | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | – | – | – | |
| – | – | – | – | +164.9% | -88.8% | +819.1% | +92.3% | -8.5% | +15.1% | +19.2% | -51.7% | |
| – | +52.4% | +24.6% | +584.7% | +36.9% | +27.8% | +173.1% | +38.8% | -16.9% | +13.6% | +14.1% | +47.9% | |
| – | +163.0% | -0.3% | +327.8% | +64.3% | +25.9% | +246.5% | +48.8% | -8.2% | +23.3% | +22.4% | -17.4% | |
| – | +4,433.5% | – | – | -5.4% | +23.9% | +3,126.5% | +28.8% | -21.5% | +101.2% | +22.4% | -84.5% | |
| – | +221.4% | +33.2% | +483.6% | +62.3% | +8.1% | +89.4% | +13.1% | +12.3% | +6.9% | +28.5% | +18.3% | |
| – | – | – | – | – | – | – | +10.1% | +3.5% | -5.5% | -15.8% | +477.8% | |
| – | -494.9% | – | +93.9% | +156.3% | -45.1% | +302.1% | +58.5% | -28.5% | -19.3% | -5.8% | +30.9% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -40.2% | -1.5% | +34.6% | +32.7% | +8.3% | +39.0% | +11.2% | +11.2% | +1.2% | +0.9% | +7.8% |
Data as of: August 14, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.